The primary benefit of CNIs in neonates is their ability to suppress inappropriate immune responses, thereby reducing inflammation and preventing tissue damage. For instance, in neonatal lupus, CNIs can help manage severe cases by controlling the autoimmune response. Similarly, in neonatal nephrotic syndrome, these drugs can reduce proteinuria and prevent kidney damage.
